NCT02543827View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of MV140

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 4, 2020

Study Completion Date

December 31, 2020

Conditions
Urinary Tract Infection Bacterial
Interventions
BIOLOGICAL

MV140

The subjects will receive daily dose of MV140 during 3 or 6 months

BIOLOGICAL

Placebo

The subjects will receive daily dose of placebo during 3 or 6 months

Trial Locations (5)

37001

Centro de Salud Universidad Centro, Salamanca

37006

Centro de Salud Capuchinos, Salamanca

37007

Hospital Universitario de Salamanca, Salamanca

37300

CENTRO DE SALUD de PEÑARANDA, Peñaranda de Bracamonte

RG1 5AN

Royal Berkshire Hospital Nhs Foundation Trust, Reading

Sponsors

Lead Sponsor

Inmunotek S.L.
All Listed Sponsors
lead

Inmunotek S.L.

INDUSTRY

NCT02543827 - Evaluation of the Efficacy and Safety of MV140 | Biotech Hunter | Biotech Hunter